Teleost Biopharmaceutical was incorporated in March 2014, as an Arizona C corporation. Teleost has offices in Tucson, AZ, and Boulder CO, and its fiscal year is the calendar year.
Teleost Biopharmaceuticals will help people project themselves from sun damage by stimulating melanin production in the body by a method not triggered by the sun’s UV rays.
Imagine having the protection and tanning effect of sunbathing with suntan lotion or sprays for a full month, even if you don’t go out in the sun! Our primary goal is to enable people to produce melanin from within, to manufacture their own photo-protective melanin, as prevention against skin maladies.
Sean Shelby CEO– Sean Shelby began his career in cancer research in 1997 at the University of Colorado, Boulder. He worked with Dr. Tad Koch and his research team focusing on the design, synthesis and evaluation of drugs targeting breast, prostate, lung, liver and pancreatic cancer especially metastic resistant cancer. Shelby has years of experience in the Department of Chemistry and Biochemistry lab especially on the discovery of the natural product, anthracycline, anti-tumor drug, doxorubicin (Adriamycin), and its reaction with formaldehyde at the amino group to form a Doxazolidine.
Mr. Shelby founded Teleost Biopharmaceutical, Inc. in 2014 with the goal of developing products to help defend against skin maladies, detecting maladies and eventually researching products to treat those maladies. Dr. Victor Hruby is co-inventor with Sean on their first patented peptide product.
- Lawrence Hecker, (Corporate Attorney)
- Quan Nugyen (Patent Attorney)
- Dr. Peter Cogen, Ph.D., (Drug Design & Delivery)